Primary human immunodeficiency virus type 1 infection

Current HIV/AIDS Reports

Volumn 2, Issue 2, 2005, Pages 55-60

  Soogoor, Malini ^b   Daar, Eric S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Acute Human Immunodeficiency Virus Infection; Human Immunodeficiency Virus; Human Immunodeficiency Virus Medicine; Primary Human Immunodeficiency Virus Infection

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

BLOOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; VIROLOGY;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL;

EID: 24144502447     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-005-0019-1     Document Type: Article

References (50)

1. US Department of Health and Human Services: CDC: HIV/AIDS surveillance report. 1999, 11:1–44.
2. Karon JM, Fleming PL, Steketee RW, De Cock KM: HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 2001, 91:1060–1068.
3. Vanhems P, Allard R, Cooper DA, et al.: Acute HIV type-1 disease as a mononucleosis-like illness: is the diagnosis too restrictive. Clin Infect Dis 1997 24:965–970.
4. Vanhems P, Dassa C, Lambert J, et al.: Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV type-1 infection. J Acquir Immune Defic Syndr 1999, 21:99–106.
5. Daar ES, Little SJ, Pitt J, et al.: Diagnosing primary HIV infection. Ann Intern Med 2001, 134:25–29.
6. Weintrob AC, Giner J, Menezes P, et al.: Infrequent diagnosis of primary HIV infection: missed opportunities in acute care settings. Arch Intern Med 2003, 163:2097–2100. This study clearly demonstrates how often the diagnosis is missed in clinical practice.
7. Rottingen JA, Cameron DW, Garnett GP: A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Trans Dis 2001, 28:579–597.
8. Richters J, Grulich A, Ellard J, et al.: HIV transmission among gay men through oral sex and other uncommon routes: case series of HIV seroconverters, Sydney. AIDS 2003, 17:2269–2271. This study describes data regarding transmission by routes that are generally thought to be low risk, emphasizing that clinicians must warn clients of all potentially risky exposures and consider this when defining who is at risk for infection.
9. Fiebig EW, Wright DJ, Rawal BD, et al.: Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871–1879. This study defines the temporal relationship between the HIV-1 infection and the development of various diagnostic markers.
10. Hecht FM, Busch MP, Rawal B, et al.: Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002, 24:1119–1129.
11. Burchell AN, Calzavara L, Ramuscak N, et al.: Symptomatic primary HIV infection or risk experiences? Circumstances surrounding HIV testing and diagnosis among recent seroconverters. Int J STD AIDS 2004, 14:601–608.
12. Pilcher CD, McPherson JT, Leone PA, et al.: Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 2002, 288:216–221.
13. Constantine NT, Sill AM, Jack N, et al.: Improved classification of recent HIV-1 infection by employing a two-stage sensitive/ less-sensitive test strategy. J Acquir Immune Defic Syndr 2003, 32:94–103.
14. Delwart E, Magierowska M, Royz M, et al.: Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 2002, 16:189–195.
15. Sagar M, Lavreys L, Baeten JM, et al.: Infection with multiple HIV type-1 variants is associated with faster disease progression. J Virol 2003, 77:12921–12926.
16. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J: Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993, 7:1035–1040.
17. Borrow P, Lewicki H, Hahn BH, et al.: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary HIV type-1 infection. J Virol 1994, 68:6103–6110.
18. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary HIV type-1 syndrome. J Virol 1994, 68:4650–4655.
19. Oxenius A, Price DA, Trkola A, et al.: Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T-cell responses and decrease in HIV 1-specific CD4+ and CD8+ T-cell frequencies. J Infect Dis 2004, 190:713–721. This study provides clinical relevance of cellular immune responses in vivo by demonstrating a relationship between loss of virologic control and immune escape.
20. Musey L, Hughes J, Schacker T, et al.: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267–1274.
21. Forthal DN, Landucci G, Daar ES: Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type-1 in the presence of naturalkiller effector cells. J Virol 2001, 75:6953–6961.
22. Abdelwahab SF, Cocchi F, Bagley KC, et al.: HIV 1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci USA 2003, 100:15006–15010.
23. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV 1-specific CD4+ T-cell responses associated with control of viremia. Science 1997, 278:1447–1450. This was the first study demonstrating the relationship between CD4+HIV 1-specific immune responses and viral control.
24. Gloster SE, Newton P, Cornforth D, et al.: Association of strong virus-specific CD4 T-cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004, 18:749–755.
25. Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181–188.
26. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385–394.
27. Brenner B, Routy JP, Quan Y, et al.: Persistence of multidrugresistant HIV-1 in primary infection leading to superinfection. AIDS 2004, 20:1653–1660.
28. Weinstock HS, Zaidi I, Heneine W, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV 1-infected persons in ten US cities. J Infect Dis 2004, 189:2174–2180. This is one of the largest cohort studies demonstrating the revalence of drug-resistant virus in those antiretroviral-naïve.
29. Turner D, Brenner B, Routy JP, et al.: Diminished representation of HIV-1 variants containing select drug resistanceconferring mutations in primary HIV-1 Infection. J Acqu Immune Defic Syndr 2004, 37:162–1631.
30. US Department of Health and Human Services: CDC: guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents February 4, 2002.
31. Hirsch MS, Brun-Vezinet F, Clotet B, et al.: Antiretroviral drug resistance testing in adults infected with HIV type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003, 37:113–128.
32. Kinloch-de Loes S, Hirschel BJ, Hoen B, et al.: A controlled trial of zidovudine in primary HIV infection. N Engl J Med 1995, 333:408–413.
33. Berrey MM, Schacker T, Collier AC, et al.: Treatment of primary HIV type-1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001, 183:1466–1475.
34. Lisziewicz J, Rosenberg E, Lieberman J, et al.: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999, 340:1683–1684.
35. Daar ES, Bai J, Hausner MA, et al.: Acute syndrome following discontinuation of antiretroviral therapy in a patient treated prior to seroconversion. Ann Intern Med 1998, 128:827–829.
36. Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523–526.
37. Kaufmann DE, Lichterfeld M, Altfeld M, et al.: Limited Durability of Viral Control following Treated Acute HIV Infection. PLoS Med 2004, 1:137–147. This was a recent study that showed that viral control after stopping therapy initiated during primary infection was not sustained in the majority of subjects.
38. Lafeuillade A, Poggi C, Hittinger G, et al.: Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 2003, 188:1426–1432.
39. Martinez-Marino B, Ashlock BM, et al.: Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection. J Clin Immunol 2004, 24:135–144.
40. Markowitz M, Jin X, Hurley A, et al.: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002, 186:634–643.
41. Rizzardi GP, Harari A, Capiluppi B, et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002, 109:681–688.
42. Smith DE, Walker BD, Cooper DA, et al.: Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004, 18:709–718. This paper provides a comprehensive overview of the pros and cons of therapy during primary HIV-1 infection.
43. Schiffer V, Deveau C, Meyer L, et al.: Recent changes in the management of primary HIV infection: results from the French PRIMO Cohort. HIV Medicine 2004, 5:326–333.
44. Jost S, Bernard M-C, Kaiser L, et al.: A patient with HIV-1 superinfection. N Engl J Med 2002, 347:731–736.
45. Altfeld M, Allen TM, Yu XG, et al.: HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002, 420:434–439.
46. Yang OO, Daar ES, Jamieson BD, et al.: HIV type-1 clade-B superinfection: evidence for differential immune containment of distinct clade-B strains. J Virol 2005, 79:860–868.
47. Smith DM, Wong JK, Hightower GK, et al.: Incidence of HIV superinfection following primary infection. JAMA 2004, 292:1177–1178.
48. Gottlieb GS, Nickle DC, Jensen MA, et al.: Dual HIV-1 infection associated with rapid disease progression. Lancet 2004, 363:619–622.
49. Tsui R, Herring BL, Barbour JD, et al.: HIV type-1 superinfection was not detected followig 215 years of injection drug user exposure. J Virol 2004, 78:94–103.
50. Gonzales MJ, Delwart E, Rhee SY, et al.: Lack of detectable HIV type-1 superinfection during 1072 person-years of observation. J Infect Dis 2003, 188:397–405.